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Translation initiation of hepatitis C virus (HCV) occurs in an internal ribosome entry site (IRES)-dependent manner. We found that HCV
IRES-dependent protein synthesis is enhanced by PD98059, an inhibitor of the extracellular signal-regulated kinase (ERK) signaling
pathway, while cellular cap-dependent translation was relatively unaffected by the compound. Treatment of cells with PD98059 allowed for
robust HCV replication following cellular incubation with HCV-positive serum. Though the molecular mechanism underlying IRES
enhancement remains elusive, PD98059 is a potent accelerator of HCV RNA replication.
D 2005 Elsevier Inc. All rights reserved.Keywords: HCV; IRES; ERK; ReplicationIntroduction
Hepatitis C virus (HCV), a member of the family
Flaviviridae, is an enveloped virus with a positive-, single-
stranded, 9.6-kb RNA genome (Murphy et al., 1995). The
virus is the major causative agent of non-A, non-B hepatitis
(Choo et al., 1989) and an estimated 170 million people
throughout the world are persistently infected. Although
acute phase HCV infection, in most cases, is asymptomatic,
the virus frequently establishes a persistent infection, which
is associated with serious clinical diseases such as chronic
hepatitis followed by liver cirrhosis and hepatocellular
carcinoma (Goodman and Ishak, 1995).
Like other positive-stranded RNA viruses, the 5V-untrans-
lated region (UTR) of HCV RNA genome functions as an
internal ribosomal entry site (IRES) and mediates translation
initiation in a cap-independent manner (Tsukiyama-Kohara
et al., 1992). Nearly the entire 5V-UTR (340 nt) and a short
sequence of the coding region downstream of the initiator
AUG codon of the HCV genome serve as an IRES (Honda0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.06.015
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E-mail address: kshimoto@virus.kyoto-u.ac.jp (K. Shimotohno).et al., 1996). Unlike encephalomyocarditis virus (EMCV) or
poliovirus, the 5V end of the HCV genome is modified by
neither cap structure nor VpG but bears a phosphate residue
(Takahashi et al., 2005).
Molecular biological investigations of HCV have been
hampered for a long time because of the lack of cell culture
system that efficiently supports HCV replication. However,
establishment of an HCV subgenomic replicon cell culture
system in 1999 (Lohmann et al., 1999) allowed for such
studies to be undertaken. The subgenomic replicon RNA is
composed of, in this order, the HCV 5V-UTR containing an
IRES, neomycin phosphate transferase or luciferase gene,
HCV nonstructural (NS) proteins 3 through 5B directed by
an EMCV IRES and the HCV 3V-UTR. As the replicon
RNA replicates autonomously in cultured cells, the system
provides a unique tool to analyze the molecular mechanisms
governing viral genome replication and protein synthesis.
Additionally, this system facilitates the screening of anti-
HCV compounds.
PD98059 was identified as a potent inhibitor of
mitogenic-extracellular signal-regulated kinase (MEK)–
extracellular signal-regulated kinase (ERK) signaling path-
way and has been widely used as a specific inhibitor of the
pathway. The MEK–ERK pathway is elicited by broad05) 105 – 115
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in various events including cell growth promotion, differ-
entiation, cell death and morphogenesis in eukaryotic cells
(reviewed in Robinson and Cobb, 1997).
In this study, we demonstrate that PD98059 enhances
HCV IRES-dependent translation. Because several lines of
evidence suggest that IRES-mediated translation regulates
replication in cultured cells (Lerat et al., 2000; He et al.,
2003) and in vivo (Lott et al., 2001; Laporte et al., 2003;
Forton et al., 2004), we examined the effect of PD98059 on
viral replication. Although the RNA levels in replicon cells
were relatively unaffected, PD98059 increased viral RNA
levels in cultured cells infected with HCV-positive serum.
Our results provide insight into the mechanisms of HCV
IRES-dependent translation initiation and, in addition,
suggest a simple infection system in cultured cells that
supports HCV replication very efficiently.Fig. 1. Constructs used in this study. Schematic representation of the HCV
RNA genome (HCV), G418-resistant subgenomic replicon (subgenomic
replicon), subgenomic luciferase-replicon (LMH14), mono-cistronic luci-
ferase expression vector with HCV IRES (IRES-luc), mono-cistronic renilla
luciferase expression vector with cap and polyA (cap-rluc-pA) or di-
cistronic plasmid-based vector construct. The ORFs are depicted as open
boxes.Results
Enhancement of luciferase-replicon or HCV IRES by
PD98059
We previously developed a highly efficient subgenomic
HCV replicon system (Murata et al., 2005). Briefly, we used
cured cells (curedMH14) as a host cell line, and the adaptive
mutations were introduced into the subgenomic replicon
construct for efficient replication. The luciferase gene was
then placed under the control of the HCV IRES for rapid,
quantitative and sensitive detection (Fig. 1, LMH14RNA).
We have used this system to screen for compounds that
inhibit HCV IRES-mediated translation. Treatment with
IFN-a, IL-1h, cyclosporin A (CsA) or TGF-h, all factors
known to repress HCV replication (Blight et al., 2000; Zhu
and Liu, 2003; Watashi et al., 2003; Murata et al., 2005),
reduced the observed luciferase activity (Fig. 2A), demon-
strating the effectiveness of this system. Conversely, the
compound PD98059 increased the luciferase activity by
348% compared to vehicle (DMSO)-treated control (Fig.
2A). The increase in luciferase activity induced by PD98059
was not apparent at 6 h after compound addition, but the
activity was significantly elevated by 12 h and remained
high for at least 3 days (Fig. 2B). Since PD98059 is an
inhibitor of the MEK–ERK pathway, we examined its
effects on ERK phosphorylation (Fig. 2C). PD98059 treat-
ment blocked ERK phosphorylation, but a clear band of
phospho-ERK was seen in DMSO-treated cells due to
growth factors present in the growth medium. Luciferase
activity increased in a dose-dependent manner following
PD98059 treatment (Fig. 2D). Treatment with the inhibitor
at 30 AM slowed cell growth (Fig. 6B) but did not put cells
to death, while >30 AM of the chemical resulted in a high
degree of toxicity (not shown). We next wished to examine
whether PD98059 specifically affected HCV IRES-medi-
ated translation. Using a plasmid based di-cistronic vector(Fig. 1 pRLIL-2), we found that PD98059 increased the
ratio of IRES-dependent translation to cap-dependent trans-
lation (Fig. 3B, 247 and 278% at 30 and 10 AM,
respectively). Translation downstream of a mono-cistronic
mRNA was also enhanced, while cap-dependent translation
was not affected (Figs. 3C,D). These results suggest that the
positive response of the luciferase-replicon is primarily
explained by increased IRES activity. Similar results were
obtained when another inhibitor of the MEK–ERK signal-
ing pathway, U0126, was used (Figs. 3E–H).
Effect of CGP57380 on HCV IRES
It has been known that either mitogen-activated protein
kinase (MAPK)-interacting protein kinase (MNK) or
eukaryotic initiation factor 4E (eIF4E)-binding protein
(4EBP) regulates translation initiation downstream of the
MEK–ERK pathway (Raught and Gingras, 1999). We first
examined the involvement of MNK in the IRES activation
using CGP57380, a specific inhibitor of MNK (Knauf et al.,
2001). ERK interacts with and phosphorylates MNK in
Fig. 2. Increased luciferase-replicon by PD98059 or U0126. (A) curedMH14 cells transfected with the luciferase-replicon RNA construct (LMH14) were
treated with DMSO (0.1%), IFN-a (100 IU/ml), IL-1h (10 ng/ml), cyclosporin A (CsA, 1 Ag/ml), SB203580 (10 AM), dexamethazone (1 AM), PD98059 (10
AM), BMP-4 (10 ng/ml), TGF-h (2 ng/ml), TGF-a (1 ng/ml), cisplatin (1 Ag/ml) or MMS (methyl methanesulfonate; 0.1 mM). Three days later, cellular
luciferase activity was measured. (B) curedMH14 cells transfected with the luciferase-replicon RNA construct were treated with DMSO (white circle),
PD98059 (10 AM, black box) or IFN-a (100 IU/ml). At the indicated times, cells were harvested for determination of luciferase activity. The activity of DMSO-
treated cells was set to 100%. (C) Western blotting analysis of phospho-ERK (upper panel) and total ERK (middle panel) in cells treated with or without
PD98059 (10 AM) for 10 h. CBB staining pattern of the same blot is used as a loading control (lower panel). (D,E) Dose-dependence of MEK–ERK inhibitors
on the activity of the luciferase-replicon. Cells transfected with the luciferase-replicon RNA construct were treated with varying concentrations of PD98059 (D)
or U0126 (E), and luciferase activity was subsequently determined. The luciferase activity was shown with the SD value of three independent experiments.
T. Murata et al. / Virology 340 (2005) 105–115 107response to growth or stress signals, respectively, and MNK
phosphorylates eIF4E (Raught and Gingras, 1999).
Cell treatment with 20 AM CGP57380 decreased the
luciferase-replicon to 34% (Fig. 4A) and the ratio of IRES-
dependent over cap-dependent value to 64% when di-
cistronic vector (Fig. 4B) was used. There was little to no
effect of lower inhibitor concentrations on translation (Figs.
4A,B,C). In order to verify the effectiveness of CGP57380,
we examined the activation of eIF4E by blotting with an
anti-phospho-eIF4E antibody. Treatment with CGP57380
clearly eliminated eIF4E phosphorylation, and a partial
reduction in eIF4E phosphorylation was seen following
treatment with PD98059, even though total eIF4E levels
were unchanged (Fig. 4D).
These data, combined with accumulating evidence
(Scheper and Proud, 2002), suggest that eIF4E phosphor-
ylation does not play a positive role in cap-dependent
translation, and, moreover, it may limit cap-dependenttranslation in cultured cells, although the physiological
significance of eIF4E phosphorylation remains controver-
sial. Nevertheless, drug-induced reduction in eIF4E phos-
phorylation did not enhance IRES-dependent translation
compared to cap-dependent translation.
Effect of 4EBP on HCV IRES
An additional key translation regulator downstream of
the MEK–ERK pathway is the eIF4E-binding protein
4EBP. When eIF4E is bound by 4EBP, ribosomes are not
recruited to the cap structure and translation is blocked.
Among the three isoforms, 4EBP1 is the best characterized.
The binding of 4EBP1 with eIF4E is controlled by the
phosphorylation state of 4EBP1, where the hypo/basal-
phosphorylated form of 4EBP1 interacts tightly with eIF4E,
but upon hyper-phosphorylation, 4EBP1 binding to eIF4E is
inhibited (Gingras et al., 2001). mTOR has been reported to
Fig. 3. Increased HCV IRES by PD98059 or U0126. Dose-dependence of MEK–ERK inhibitors on the activity of the di-cistronic pRLIL-2 vector (A,B,E,F)
and mono-cistronic expression vectors (C,D,G,H). (A,E) Cells transfected with di-cistronic pRLIL-2 were incubated with varying concentrations of PD98059
(A) or U0126 (E), and luciferase activity was subsequently determined. IRES-dependent firefly luciferase activity is shown in white, and cap-dependent renilla
luciferase activity is in black. (B,F) The results in panels (A) and (E) are shown as the ratio of IRES-dependent over cap-dependent value, respectively. (C,G)
Cells transfected with mono-cistronic IRES-luc (white bar) and cap-rluc-pA (black bar) were incubated with varying concentrations of PD98059 (C) or U0126
(G), and luciferase activity was subsequently determined. (D,H) The results in panels (C) and (G) are shown as the ratio of IRES-dependent over cap-dependent
value, respectively. The luciferase activity was shown with the SD value of three independent experiments.
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Herbert et al. (2002) proposed that ERK is involved in the
hyper-phosphorylation of 4EBP1.
We investigated a possible role for 4EBP1 in the
observed IRES activation by PD98059. Exogenous expres-
sion of wild type or dominant active form of 4EBP1 (T46A,
Mothe-Satney et al., 2000) elevated the luciferase-replicon
to 420 and 325% of control levels, respectively, and
PD98059 treatment enhanced these effects (Fig. 5A). A
mutant form of 4EBP1 unable to interact with eIF4E (mBD,
Mader et al., 1995), however, did not affect the luciferase-
replicon activity (Fig. 4A). Luciferase expression driven by
a di-cistronic vector resulted in a similar trend (Fig. 5C).Fig. 4. Effect of CGP57380 on luciferase-replicon or HCV IRES. (A) Cells t
CGP57380 (AM). Three days after transfection, cells were harvested for determin
100%. (B) Cells transfected with di-cistronic pRLIL-2 were incubated with CGP5
firefly luciferase activity is shown in white, and cap-dependent renilla luciferase ac
dependent over cap-dependent value. The luciferase activity was shown with th
performed to examine the phosphorylation of eIF4E (upper panel) and total eIF4E
staining pattern of the same blot is used as a loading control.Both the wild type and mBD forms of 4EBP1 were hyper-
phosphorylated (Fig. 5D). In the cell line used, Huh-7,
endogenous 4EBP1 was not detected (Fig. 5D, vec). The
expression levels of wild-type and T46A were reduced
compared to mBD, likely as a result of the auto-suppression
of cap-dependent translation by the wild type or T46A
4EBP1.
We next tried to eliminate endogenous 4EBP. Knock-
down of 4EBP was confirmed following individual siRNA
(Fig. 6A) or all siRNAs treatment (Fig. 6B). Among the
different 4EBP isoforms, knock-down of 4EBP2 led to the
strongest reduction in the luciferase-replicon (Figs. 6C,D)
and the IRES/cap-translation in the di-cistronic vector (Figs.ransfected with the luciferase-replicon RNA construct were treated with
ation of luciferase activity. The activity of DMSO-treated cells was set to
7380, and luciferase activity was subsequently determined. IRES-dependent
tivity is in black. (C) The results in panel (B) are shown as the ratio of IRES-
e SD value of three independent experiments. (D) Western blotting was
(middle panel) in cells treated with or without CGP57380 (20 AM). CBB
Fig. 5. Effect of exogenous expression of 4EBP on luciferase-replicon or HCV IRES. (A) Cells were transfected with the luciferase-replicon RNA construct
together with empty vector (vec), vector for 4EBP1, 4EBP1T46A or 4EBP1mBD. 4EBP1T46A is a dominant-active form of 4EBP1, and 4EBP1mBD lacks the
ability to bind with eIF4E. Cells were harvested for determination of luciferase activity after 3 days incubation with PD98059 (10 AM). White and black bars
indicate absence and presence of PD98059, respectively. The data are normalized by cotransfection with the pRL-TK. (B) Cells were cotransfected with di-
cistronic pRLIL-2 together with empty vector (vec), vector for 4EBP1, 4EBP1T46A or 4EBP1mBD. Luciferase activity was subsequently determined. IRES-
dependent firefly luciferase activity is shown in white, and cap-dependent renilla luciferase activity is in black. (C) The results in panel (B) are shown as the
ratio of IRES-dependent over cap-dependent value. White and black bars indicate absence and presence of PD98059, respectively. The luciferase activity was
shown with the SD value of three independent experiments. (D) Western blotting was performed to examine the expression and phosphorylation state of 4EBP
in cells using anti-4EBP antibody. CBB staining pattern of the same blot is used as a loading control.
T. Murata et al. / Virology 340 (2005) 105–115 1096G,H). Huh-7 cells express higher levels of 4EBP2
compared to the other isoforms, and we hypothesize that
this may account for the observed effect.
The above results suggest that 4EBP proteins, partic-
ularly 4EBP2 in this cell line, play an important role in HCV
IRES-mediated translation. However, no evidence impli-
cated 4EBP in the ERK-mediated modification of IRES
activity because, even in the presence of the mBD mutant or
the elimination of 4EBP isoforms, PD98059-mediated
activation of IRES-dependent translation still occurred.
Effect of PD98059 on G418-resistant subgenomic replicon
Since IRES-mediated translation can regulate RNA
replication in cultured HCV replicon cells (He et al.,
2003), we tested the effect of PD98059 on G418-resistant
replicon RNA replication. When monitored by either real-
time RT-PCR (Fig. 7A) or Northern blotting (Fig. 7C),
replicon RNA was increased up to 210% of vehicle-treated
control by the administration with 30 AM of PD98059 for
24 h. The replicon RNA levels decreased at 48 h or later
probably because of the cell growth suppression (Fig. 7B).
Additionally, PD98059 induced the production of viral
protein NS5A (Fig. 7D). Although replicon RNA levels can
fluctuate and are not the most stringent test, as Zhu and Liu
(2003) also observed, the observed up-regulation of HCV
replicon RNA and a viral protein at 24 h strongly suggests
an effect of PD98059.
PD9805 promotes HCV multiplication in a model of HCV
infection
To examine the effects of PD98059 on HCV replication,
we infected curedMH14 (Fig. 8A), Huh-7 (B), OUMS-29
H-11 (C) or PH5CH8 (D) cells with HCV-positive serum for
1 day and incubated cells with either PD98059 or vehicle.curedMH14 had been prepared by curing an HCV replicon
cell line of replicon RNA (Murata et al., 2005). OUMS-29/
H-11 is a human hepatocyte cell line, in which SV40 large T
antigen and hepatocyte nuclear factor 4 (HNF4) had been
introduced by stable transfection (Inoue et al., 2001), and
PH5CH8 is a human hepatocyte line that hat had been
immortalized with SV40 large T antigen (Ikeda et al., 1998).
HCV replication efficiency is highly dependent on the
cell culture conditions, and poor infectivity can lead to little
or no replication. However, HCV infectivity was dramati-
cally improved by the addition of 30 AM PD98059 (Fig. 8).
With 30 AM PD98059, virus RNA levels on day 5 were 162,
113 and 146% of the levels of day 1, whereas they were 0,
33 and 0% in curedMH14, OUMS-29 H-11 and PH5CH8
cells treated with DMSO, respectively. Thus, HCV repli-
cation was increased by 100-fold or more in curedMH14
and PH5CH8 cells on the fifth day. Huh-7 cells were not as
permissive for viral infection under these conditions.Discussion
In this study, we found that the addition of PD98059, an
inhibitor of the MEK–ERK pathway, enhanced HCV IRES-
dependent translation and HCV replication in cultured cells.
Multiple cellular factors bind directly to the HCV IRES
including eIF3 (Sizova et al., 1998), the 40S ribosome (Otto
et al., 2002), polypyrimidine tract-binding protein (PTB, Ali
and Siddiqui, 1995), La autoantigen (Ali and Siddiqui,
1997) and heterogeneous nuclear ribonucleoprotein L
(hnRNP L, Hahm et al., 1998). Some of these molecules
may play a role in the PD98059-mediated activation of
HCV IRES-dependent translation.
Several reports have suggested that translation driven by
the HCV IRES (Honda et al., 2000), as well as other IRESes
(Pyronnet et al., 2000; Cornelis et al., 2000), is highest in
Fig. 6. Effect of RNAi knock-down of 4EBPs on luciferase-replicon or HCV IRES. (A) Cells were transfected with control siRNA (si cont) or si4EBP1, 2 or 3,
independently. Total RNAwas collected to examine the levels of relevant 4EBP RNA by RT-PCR. (B) Cells were transfected with control siRNA (si cont) or
si4EBP1, 2 and 3, altogether. Total RNAwas collected to examine the levels of every isoform of 4EBP RNA by RT-PCR. (C,D) Cells were cotransfected with
LMH14 luciferase-replicon RNA construct and various siRNAs, independently (C) or together (D). Luciferase activity was determined after 3 days incubation
with or without 10 AM PD98059. White and black bars indicate absence and presence of PD98059, respectively. The data are normalized by cotransfection
with the pRL-TK. (E,F) Cells were cotransfected with di-cistronic pRLIL-2 together with various siRNAs, independently (E) or together (F). Luciferase activity
was subsequently determined. IRES-dependent firefly luciferase activity is shown in white, and cap-dependent renilla luciferase activity is in black. (G,H) The
results in panels (E) and (F) are shown as the ratio of IRES-dependent over cap-dependent value. White and black bars indicate absence and presence of
PD98059, respectively. The luciferase activity was shown with the SD value of three independent experiments.
T. Murata et al. / Virology 340 (2005) 105–115110the mitotic phase (G2/M) and relatively lower in other
phases of the cell cycle. Since the MEK–ERK signaling
pathway is largely suppressed in the G2 phase (Tamemoto
et al., 1992), MEK–ERK signaling may also be a key
regulator of this phenomenon.In addition to ERK signaling, p38 MAPK and JNK
signaling pathways are also involved in translation regu-
lation. Cellular stress negatively affects cap-dependent
protein synthesis (Patel et al., 2002), while EMCV (Hirasawa
et al., 2003) or c-myc (Subkhankulova et al., 2001) IRES-
Fig. 7. Effect of PD98059 on G418-resistant subgenomic replicon. (A)
MH14, a G418-resistant subgenomic replicon cell line, was treated with
DMSO (white circle), 30 AM PD98059 (X), 10 AM PD98059 (black box) or
100 IU/ml IFN-a (white triangle) for 1, 3, 5 or 7 days. Following the
extraction of total RNA, the quantity of HCV replicon RNAwas determined
by real-time RT-PCR analysis. (B) In parallel with the experiments in Fig.
5A, cells were treated with DMSO (white circle), 30 AM PD98059 (X),
10 AM PD98059 (black box) or 100 IU/ml IFN-a (white triangle). Cell
numbers were counted at the indicated time points. (C) Total RNA of cells
treated for 1 day was also subjected to Northern blot analysis (upper panel).
The ethidium bromide staining of ribosomal RNA is shown as an internal
control (lower panel). (D) Total protein of cells treated for 1 day was
harvested to examine the amount of NS5A (upper panel). CBB staining
pattern of the same blot is shown as a loading control (lower panel).
Fig. 8. Increased HCV multiplication by PD9805 in cells infected with
HCV-positive serum. curedMH14 (A), Huh-7 (B), OUMS-29 H-11 (C) or
PH5CH8 (D) cells were infected or mock-infected (white triangle) with
HCV-positive serum for 1 day. After extensive washing with PBS, the cells
were cultured with fresh medium supplemented with DMSO (white circle),
30 AM PD98059 (X), 10 AM PD98059 (black box). At the indicated times,
total RNAwas extracted, and the quantity of HCV RNAwas determined by
real-time RT-PCR analysis.
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fore, these signaling pathways may also affect HCV IRES-
dependent translation.
A cell culture system supporting HCV replication has
not existed for some time. When immortalized hepatocyte
cell lines are infected with HCV, viral replication
efficiency is not high despite high replication rates in
patients. Many researchers have attempted to solve this
problem. Ikeda et al. (1998) demonstrated that incubation
of cells at lower temperature helps virus replication.
Aizaki et al. (2003) used a three-dimensional hepatocyte
culturing system. Others varied the bovine serum levels,
vitamins, lipids or amino acid composition or the pH of
the culture medium. We observed that freshly thawed
cells with lower viability supported replication better than
rapidly growing cells. We now propose a simple infection
system that supports highly efficient HCV replication in
cultured cells by adding PD98059 in the medium.
Cells isolated from human liver are cultured in
conditions that substantially differ from the in vivoenvironment and are often immortalized by oncogene
expression. Consequently, many signaling pathways are
likely aberrantly regulated in vitro. Among these path-
ways, it seems likely that ERK signaling is responsible
for regulating HCV replication in cultured cells, and
PD98059 may help mimic the in vivo environment and
facilitate HCV replication by enhancing IRES-dependent
translation.
Although treatment with PD98059 increased the
replication of viral RNA in various cell lines when
infected with HCV-positive serum (Fig. 8), replicon
RNA levels were not increased under similar conditions
(Fig. 7). The RNA copy number may explain these
differences. PD98059 may not enhance the replication of
replicon RNA because, in these systems, viral RNA and
proteins are abundant even in the absence of the inhibitor.
In cells infected with patient serum, highly efficient IRES-
dependent translation may be essential for viral replication
due to the low copy number of viral RNA per cell.
Mutations of serine residues within NS5A that affect
the protein hyper-phosphorylation enhance replication of
the virus replicon (Blight et al., 2000), and inhibitors of
NS5A kinase(s) activate replication (Neddermann et al.,
2004). Since the CMGC group of serine–threonine
kinases has been implicated in the phosphorylation of
NS5A (Reed et al., 1997), PD98059 might affect the
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replication. When we treated cells with PD98059,
however, the levels of hyper-phosphorylated NS5A were
not affected (not shown). This suggests that PD98059
activates viral replication through the enhancement of
IRES-mediated translation but not through a reduction in
phosphorylation state of NS5A.
Multiplication of influenza virus (Pleschka et al., 2001),
borna disease virus (Planz et al., 2001), coxsackievirus
(Luo et al., 2002), visna virus (Barber et al., 2002), human
immunodeficiency virus (Montes et al., 2000), vaccinia
virus (de Magalhaes et al., 2001), Epstein–Barr virus (Gao
et al., 2001), cytomegalovirus (Rodems and Spector, 1998)
and human herpesvirus-8 (Akula et al., 2004) are promoted
by MEK–ERK signaling pathway activation. Activation of
this pathway results in efficient cell cycle promotion, high
cellular or viral gene production and increased availability
of biomaterials, such as nucleotides or amino acids. Many
of these viruses, therefore, likely exploit the cellular
environment created through the activation of the MEK–
ERK pathway. Interestingly, replication of the hepatitis B
virus (HBV) is negatively regulated by the MAPK
signaling pathway (Zheng et al., 2003). Because both
HBV and HCV infect the same target organ, it is possible
that both viruses have evolved similar means to exploit
host signaling pathways. Much research is needed to
identify the factors conferring organ specificity to HCV,
however.Materials and methods
Cell culture, antibodies and reagents
Huh-7 or curedMH14 cells (Murata et al., 2005) were
maintained in Dulbecco’s modified Eagle medium (Invitro-
gen, Carlsbad, CA) supplemented with 10% fetal bovine
serum, 100 units/ml nonessential amino acids (Invitrogen,
Carlsbad, CA) and 100 Ag/ml penicillin and streptomycin
sulfate (Invitrogen, Carlsbad, CA). MH14 replicon cells
(Miyanari et al., 2003) were cultured in the same medium
with 300 Ag/ml G418 (Geneticin, Invitrogen, Carlsbad, CA).
OUMS-29/H-11 cells (Inoue et al., 2001, Fukaya et al., 2001)
were maintained in ASF-104 medium (Ajinomoto, Tokyo,
Japan) with 100 Ag/ml penicillin and streptomycin sulfate
(Invitrogen, Carlsbad, CA), and PH5CH8 cells were cultured
as described (Ikeda et al., 1998).
Rabbit anti-ERK, rabbit anti-phospho-ERK, rabbit anti-
eIF4E and mouse anti-phospho-eIF4E antibodies were
purchased from Cell Signaling Technology (Beverly, MA).
Rabbit anti-4EBP antibody was from Santa Cruz Biotech-
nology (Santa Cruz, CA). Horseradish-peroxidase-linked
goat antibodies to mouse or rabbit IgG were from
Amersham Biosciences (Piscataway, NJ). PD98059 and
other inhibitors were obtained commercially from Calbio-
chem-Novabiochem (San Diego, CA).Plasmid construction
The pLMH14, used to synthesize the luciferase-replicon
LMH14 RNA and mono-cistronic IRES-luc RNA, has been
described previously (Murata et al., 2005). The di-cistronic
plasmid vector, pRLIL-2, was based on the pRL-CMV
Vector (Promega, Madison, WI) and contains HCV IRES
sequence (complete 5V-UTR sequence and initial part of the
Core gene) plus the firefly luciferase sequence obtained
from pGL2 Vector (Promega, Madison, WI).
The human 4EBP1 gene was cloned by RT-PCR into
the mammalian expression vector pcDNA3 (Invitrogen,
Carlsbad, CA) to obtain pcDNA4EBP. Primers used to
clone the gene were 5V-cggaattcgatgtccgggggcagcagctgc-3V
and 5V-ctgactcgagttaaatgtccatctcaaactgtg-3V. To generate
pcDNS4EBPT46A and pcDNA4EBPmBD plasmids,
mutations were inserted into pcDNA4EBP by PCR-based
site-directed mutagenesis using the primers 5V-ctggtacc-
tcccggggcggtgctgaagagcgtg-3V for T46A and 5V-gaggtac-
caggatcatctatgaccggaaattcgcggcggagtgtcggaactc-3V for
mBD. Bold letters in the primers denote the substituted
nucleotides.
RNA synthesis in vitro
In order to synthesize the LMH14 luciferase-replicon
RNA or mono-cistronic IRES-luc RNA, pLMH14 was
digested with XbaI or KpnI, respectively, and subjected to in
vitro transcription using a MEGAscript T7 kit (Ambion,
Austin, TX) according to the manufacturer’s instructions.
Following DNase treatment, RNA was purified by lithium
chloride precipitation. For production of mono-cistronic
cap-rluc-pA RNA, the pRL-TK Vector (Promega, Madison,
WI) was cut with XbaI and transcribed in vitro using
mMESSAGE mMACHINE T7 Kit (Ambion, Austin, TX)
for capping. Poly(A) Tailing Kit (Ambion, Austin, TX) was
then used for polyadenylation of the RNA.
Luciferase assay
Lipofection with RNA was performed using DMRIE-C
reagent (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instructions. Plasmid DNA, including
pRLIL-2, was transfected into cells using FuGENE6 reagent
(Roche, Indianapolis, IN). Luciferase activity was measured
using a Dual-Luciferase Reporter Assay System (Promega,
Madison, WI). Assays were performed in triplicate; standard
deviations are denoted by bars in the figures.
Real-time RT-PCR analysis
Total RNA was extracted from cells using Sepasol
RNAI super reagent (Nacalai Tesque, Kyoto, Japan)
according to the manufacturer’s protocol. The 5V-UTR of
HCV genomic RNA was quantified with the ABI PRISM
7700 sequence detector (Applied Biosystems, Foster City,
T. Murata et al. / Virology 340 (2005) 105–115 113CA) as described (Watashi et al., 2003) using the 5V-
CGGGAGAGCCATAGTGG-3V (forward) and 5V-AGTAC-
CACAAGGCCTTTCG-3V (reverse) primers and the fluo-
rogenic probe 5V-CTGCGGAACCGGTGAGTACAC-3V.
As an internal control, ribosomal RNA was quantified
using TaqMan ribosomal RNA control reagents (Applied
Biosystems, Foster City, CA).
Northern and Western blot analysis
Total RNAwas extracted from cells using Sepasol RNAI
super reagent (Nacalai Tesque, Kyoto, Japan). Northern or
Western blot analysis was performed as described previ-
ously (Kishine et al., 2002). The 1.5-kb EcoRI fragment of
pNNRZ2 was used as the probe, which corresponds to the
C-terminal half of the NS5A gene and N-terminal half of the
NS5B gene.
In vitro HCV infection
The in vitro HCV infection experiment was carried out as
described previously (Watashi et al., 2003). In short, cells
were infected with the serum which was prepared from an
HCV-positive blood donor. At 24 h post-inoculation, the
cells were washed three times with PBS and maintained
with fresh medium with DMSO or PD98059 until the
extraction of the RNA sample.
siRNA
Sequences of siRNAs (Invitrogen, Carlsbad, CA) were
as follows: 5V-aactcacctgtgaccaaaaca-3V for 4EBP1, 5V-
aagactccaaagtagaagtaa-3V for 4EBP2 and 5V-aagctggagtg-
caagaactca-3V for 4EBP3. Before using, the siRNAs were
dissolved in RNase-free water, denatured once at 98 -C for
1 min and annealed at 37 -C for 1 h. For electroporation of
siRNA, 4  105 cells and 0.8 Ag siRNA were suspended in
400 Al of OPTI-MEM (Invitrogen, Carlsbad, CA) and
pulsed at 250 V and 950 AF using GenePulser (Bio Rad,
Hercules, CA) at 4 -C. To evaluate the silencing effects of
siRNAs, RT-PCR was performed using One-Step RT-PCR
Kit (TaKaRa, Ohtsu, Japan) according to the manufacturer’s




4EBP3, 5V-cggaattcatgtcaacgtccactagctg-3V and 5V-ctgactc-
gagttagatgtccatttcaaattg-3V, GAPDH, 5V-tttctcgagatggg-
gaaggtgaaggtcg-3V and 5V-ccggaattctggagggatctcgctcctg-3V.Acknowledgments
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